home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Ensysce Biosciences, Inc. - Common Stock (NQ:ENSC)

1.020 -0.040 (-3.77%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ensysce Biosciences, Inc. - Common Stock

< Previous 1 2

...

9 10 11 12 13 14 15 16 Next >

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

September 14, 2022

We're starting off Wednesday with an overview of the biggest pre-market stock movers this morning and the news moving those shares!

Via InvestorPlace

Why Kaspien Holdings Is Trading Lower By 13%; Here Are 21 Stocks Moving Premarket ↗

September 14, 2022

Gainers Aditxt, Inc. (NASDAQ: ADTX) rose 54.3% to $28.56 in pre-market trading following effect of 1:50 reverse stock split.

Via Benzinga

Ensysce Biosciences Announces Results of Special Meeting of Stockholders

September 08, 2022

Via ACCESSWIRE

Ensysce Biosciences Reminds Shareholders to Vote at Upcoming Special Meeting

September 06, 2022

Via ACCESSWIRE

Ensysce Biosciences, Quotient Partner To Work On Novel Opioid To Prevent Abuse and Overdose ↗

September 01, 2022

Via Benzinga

Ensysce Biosciences Announces Completion of Clinical Portion of Human Abuse Potential Trial PF614-103

August 23, 2022

Via ACCESSWIRE

Ensysce Biosciences Releases Updated Investor Presentation Ahead of Corporate Update Call

August 17, 2022

Via ACCESSWIRE

Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday ↗

September 14, 2022

Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX...

Via Benzinga

Ensysce Biosciences Debuts Redesigned Company Website to Highlight its TAAP(TM) and MPAR(TM) Technologies and Growing Product Pipeline

August 31, 2022

Via ACCESSWIRE

Ensysce Biosciences Provides Business Update and Reports Second Quarter 2022 Financial Results

August 11, 2022

Via ACCESSWIRE

Why ShiftPixy Surged Around 177%; Here Are 71 Biggest Movers From Yesterday ↗

September 09, 2022

Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 176.5% to close at $31.00 on Thursday after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to...

Via Benzinga

Ensysce Biosciences, Inc. Announces Participation in Upcoming Conferences

August 24, 2022

Via ACCESSWIRE

Why Bilibili Is Trading Lower By Over Around 14%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session ↗

September 08, 2022

Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 73.8% to $19.48 after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to shareholders.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

August 18, 2022

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

August 18, 2022

It's time to take a look at the biggest pre-market stock movers for Thursday and the news that's got those shares moving!

Via InvestorPlace

This Biotechnology Stock Tumbled 37%; Here Are 70 Biggest Movers From Yesterday ↗

August 19, 2022

Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares climbed 135.9% to close at $2.17 on Thursday.

Via Benzinga

Why Is Disney Higher By More Than 7%: Here Are 40 Stocks Moving Premarket ↗

August 11, 2022

Gainers

Via Benzinga

Why FlexShopper Surged Over 47%; Here Are 104 Biggest Movers From Yesterday ↗

August 12, 2022

Gainers Digital Media Solutions, Inc. (NYSE: DMS) jumped 78.8% to close at $2.11. Digital Media Solutions recently reported worse-than-expected Q2 EPS and sales results.

Via Benzinga

Why Matterport Is Trading Higher By Around 25%, Here Are 73 Stocks Moving In Thursday's Mid-Day Session ↗

August 11, 2022

Gainers Timber Pharmaceuticals, Inc. (NYSE: TMBR) shares rose 63.8% to $0.1769. Timber Pharmaceuticals recently announced closing of $8.0 million public offering.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

August 11, 2022

Good morning! We're starting off Thursday with an overview of the biggest pre-market stock movers that traders need to watch!

Via InvestorPlace

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

August 09, 2022

Via Benzinga

Ensysce Biosciences Announces Completion of $8 Million Convertible Note Financing

August 09, 2022

Via ACCESSWIRE

Recap of Wednesday's Biotech Catalysts - End of The Day Summary ↗

July 27, 2022

Via Benzinga

Why Avalo Therapeutics Surged 32%; Here Are 111 Biggest Movers From Yesterday ↗

August 10, 2022

Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 60.1% to settle at $7.27 on Tuesday after the company was granted US patent for an air treatment system and method.

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

August 05, 2022

On Friday, 72 companies set new 52-week lows.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

July 27, 2022

Gainers

Via Benzinga

Ensysce Biosciences Announces Positive Bioequivalence (BE) Study Data of Novel "TAAP" Opioid PF614 and Provides Timing of Corporate Update Call

July 27, 2022

Via ACCESSWIRE

Ensysce Biosciences Announces Positive Bioequivalence (BE) Study Data of Novel "TAAP" Opioid PF614 and Provides Timing of Corporate Update Call

July 27, 2022

~ BE Study of PF614 Represents Critical Progress Toward FDA Approval ~~ Supports the 505(b)(2) Regulatory Path for Clinical Development of PF614 ~SAN DIEGO, CA / ACCESSWIRE / July 27, 2022 / Ensysce...

From Ensysce Biosciences, Inc.

Via AccessWire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

July 15, 2022

Gainers

Via Benzinga

Ensysce Biosciences Announces Initial Patients Dosed of First Human Abuse Potential Study

July 13, 2022

~ Trial Designed to Test and Confirm Nasal Opioid Manipulation ~

From Ensysce Biosciences, Inc.

Via AccessWire

< Previous 1 2

...

9 10 11 12 13 14 15 16 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com